Sara Nunez-Garcia

Founding Partner at Forty51 Ventures

Sara is co-Founder and Partner at Forty51 Ventures, a Biotech venture fund focused on venture formation in Europe.

Previously, Sara served as VP Investments at Roivant where she led investments and divestments across several therapeutic areas in the Biotech space. Sara served on the board of Altavant (acquired by Sumitomo), Spirovant (acquired by Sumitomo), Urovant, Kinevant and Lysovant. Prior, Sara served as Principal with Sofinnova Partners. She invested in Delinia Bio (acquired by Celgene), ProQR Therapeutics [PRQR], Auris Medical [EARS], MedDay Pharma, ObsEva [OBSV], Enyo Pharma, Asceneuron, MyTomorrows, Leucid Bio and Comet Therapeutics (acquired by Vectiv Bio). She served on the Board in several portfolio companies.

Sara spent seven years in the Pharma industry in a preclinical development role and was also an Associate in the Licensing and M&A team at Onyx Pharmaceuticals (now Amgen) in California.

In addition, Sara did her postdoctoral fellow in the Biochemistry and Biophysics departments at the Albert Einstein College of Medicine in New York where she developed several inhibitors for oncology targets, one of which was in-licensed by Biocryst and is currently in clinical development. Sara received her PhD in Chemistry from the University of Manchester, UK. In addition, Sara holds an MBA from INSEAD.